Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

Rhea-AI Summary

ProPhase Labs (OTC: PRPH) invites investors to a live webinar on February 3, 2026 at 4:15 p.m. ET hosted by RedChip Companies featuring Chairman & CEO Ted Karkus. The presentation will review recent milestones including full U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test.

Other topics include a strategic initiative to recover more than $50 million in COVID-19 receivables, Nebula Genomics and planned commercialization of BE-Smart™, plus expansion of DNA Complete® and DNA Expand™ product lines.

Key Figures

Addressable market: $7–14 billion COVID-19 receivables: more than $50 million Webinar date: February 3, 2026 +1 more

4 metrics

Addressable market $7–14 billion BE-Smart Esophageal Cancer Test market opportunity

COVID-19 receivables more than $50 million Strategic initiative with Crown Medical Collections

Webinar date February 3, 2026 Live investor webinar and Q&A session

Webinar time 4:15 p.m. ET Scheduled start time for investor webinar

Market Reality Check

Price: $0.1550 Vol: Trading volume of 164,162...

low vol

$0.1550 Last Close

Volume Trading volume of 164,162 shares is below the 20-day average of 708,652 shares ahead of this upbeat webinar announcement. low

Technical Shares at $0.155 are trading below the 200-day moving average of $3.04 and far under the $7.80 52-week high.

Peers on Argus

Peer performance is mixed: PRPO and ADVB are modestly positive, ISPC is up 6.14%...

1 Down

Peer performance is mixed: PRPO and ADVB are modestly positive, ISPC is up 6.14%, while NOTV and BIAF are down, and momentum scans only flag XWEL moving down sharply. This pattern points to stock-specific dynamics for PRPH rather than a unified sector move.

Historical Context

5 past events · Latest: Jan 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 26	Collections update	Positive	-19.3%	Detailed progress on Crown Medical COVID-19 receivables recovery efforts.
Jan 22	OTC uplisting	Positive	+53.0%	Approval and uplisting from Pink Sheets to the OTC market.
Jan 05	Capital structure update	Neutral	-22.8%	Update on convertible debt conversions, reverse split, and asset value.
Dec 19	Reverse merger LOI	Neutral	-14.7%	Non-binding LOI for proposed reverse merger with ABL.
Dec 19	Merger LOI notice	Neutral	-14.7%	ABL Diagnostics announcement detailing LOI terms and conditions.

Pattern Detected

Recent news, often focused on balance sheet and strategic updates, has frequently been followed by negative price moves, with the OTC uplisting being a notable positive outlier.

Recent Company History

Over the past several months, ProPhase has focused on capital structure, collections, and strategic repositioning. Updates on Crown Medical Collections highlighted potential net recoveries above $50M, yet the Jan 26, 2026 update saw a sharp decline. The Jan 22, 2026 uplisting to the OTC market drove a strong gain of 53.03%. Earlier communications detailed significant convertible debt conversions, a 1-for-10 reverse split, and a proposed reverse merger with Advanced Biological Laboratories. Today’s investor webinar invitation continues this pattern of active communication around assets like BE-Smart and Crown Medical.

Market Pulse Summary

This announcement highlights ProPhase’s efforts to showcase its portfolio, including the BE-Smart es...

Analysis

This announcement highlights ProPhase’s efforts to showcase its portfolio, including the BE-Smart esophageal cancer test with a stated $7–14 billion addressable market and Crown Medical’s work to recover more than $50M in COVID-19 receivables. It follows months of capital-structure adjustments, uplisting to the OTC market, and detailed updates on collections. Investors monitoring this story may focus on progress toward BE-Smart commercialization, actual cash recoveries, and performance at Nebula Genomics and related DNA products.

Key Terms

molecular diagnostics, genomics, clinical validation, esophageal cancer, +1 more

5 terms

molecular diagnostics medical

"assets spanning molecular diagnostics, genomics, and consumer health."

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

genomics medical

"assets spanning molecular diagnostics, genomics, and consumer health."

The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.

clinical validation medical

"full U.S. patent approval and clinical validation of its BE-Smart™ Esophageal Cancer Test"

Clinical validation is the process of proving a medical test, device, or treatment reliably detects or predicts a health condition in real patients and settings, not just in theory or the lab. For investors it matters because successful validation lowers regulatory and adoption risk—like field-testing a new car to show it runs safely on real roads—making commercial use, reimbursement and revenue far more likely.

esophageal cancer medical

"BE-Smart™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection"

Esophageal cancer is a disease in which abnormal cells grow uncontrollably in the esophagus, the muscular tube that carries food from the throat to the stomach. Think of it as a blockage or damage forming inside a pipe that can disrupt function and require surgery, drugs, or medical devices. Investors care because its incidence, treatment advances, clinical trial results and regulatory approvals directly affect demand, costs, company revenues and valuations in healthcare markets.

dna datasets medical

"Nebula Genomics, which houses one of the world’s largest and most diverse DNA datasets."

DNA datasets are large collections of individual genetic information—like a searchable library of biological blueprints—assembled from medical tests, research studies, or consumer samples. For investors they matter because these datasets power development of new diagnostics, drugs and personalized treatments, create potential revenue through licensing or partnerships, and carry regulatory and privacy risks that can affect a company’s value and competitive edge.

AI-generated analysis. Not financial advice.

UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature ProPhase Labs Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase’s dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approval and clinical validation of its BE-Smart^™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection in a $7–14 billion addressable market. The presentation will also cover ProPhase’s strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, its streamlined cost structure, and its consumer genomics business Nebula Genomics, which houses one of the world’s largest and most diverse DNA datasets. With multiple near-term catalysts, including the planned commercialization of BE-Smart^™ and expansion of its DNA Complete^® and DNA Expand^™ product lines, ProPhase is positioned to unlock significant shareholder value as a lean, innovation-driven healthcare company.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/PRPH/89160870488

Questions can be pre-submitted to PRPH@redchip.com or online during the live event.

About ProPhase Labs Inc.

ProPhase Labs Inc. (OTC: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com.

Forward-Looking Statements

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Details about these risks and uncertainties can be found in our filings with the SEC. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor Relations Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
PRPH@redchip.com

Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

FAQ

When is the ProPhase Labs (PRPH) investor webinar and who will present?

The webinar is scheduled for February 3, 2026 at 4:15 p.m. ET with Chairman and CEO Ted Karkus presenting. According to the company, RedChip Companies will host the live event and it includes a Q&A session for investors.

What did ProPhase (PRPH) announce about the BE-Smart™ Esophageal Cancer Test?

ProPhase announced full U.S. patent approval and clinical validation for the BE-Smart™ test. According to the company, the diagnostic targets early esophageal cancer detection in a reported $7–14 billion addressable market and is planned for near-term commercialization.

What is ProPhase’s (PRPH) update on COVID-19 receivables recovery with Crown Medical Collections?

ProPhase said it has a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables. According to the company, this initiative is intended to improve collections and strengthen the company’s balance sheet.

How will ProPhase (PRPH) commercialize BE-Smart™ and expand its product lines?

ProPhase plans near-term commercialization of BE-Smart™ alongside expansion of DNA Complete® and DNA Expand™ product lines. According to the company, these actions are positioned as catalysts to drive revenue and shareholder value as a lean healthcare company.

What does ProPhase (PRPH) say about Nebula Genomics and its dataset?

ProPhase states Nebula Genomics houses one of the world’s largest and most diverse DNA datasets. According to the company, the asset supports its consumer genomics business and product development for DNA Complete® and DNA Expand™ offerings.

How can investors register or submit questions for the ProPhase (PRPH) webinar?

Investors can register for the free webinar via the provided RedChip registration link and may pre-submit questions by email. According to the company, live questions are also accepted during the event and pre-submissions can be sent to PRPH@redchip.com.